Friday, October 12, 2012

13:00 – 13:15	Welcome and Introductions Carla Baan, PhD, <i>Rotterdam, The Netherlands</i> Roslyn Mannon, MD, <i>Birmingham, United States</i>
13:15 – 13:45	Keynote Address Cell Therapy in Transplantation: The Time is Here Edward Geissler, PhD, <i>Regensburg, Germany</i>
13:45 – 15:15	<b>Optimizing Costimulation Blockade</b> Chairs: Barbara Murphy, MD, <i>New York, United States</i> and Thomas Wekerle, MD, <i>Vienna, Austria</i>
13:45	Costimulation Blockade: Review of Clinical Trials Lionel Rostaing, MD, PhD, <i>Toulouse, France</i>
14:15	Improving Clinical Outcomes of Costimulation Blockade: Lessons from the Bench Mohamed Sayegh, MD, <i>Boston, United States and Beirut, Lebanon</i>
14:45	New Costimulation Blockades: Anti CD40 and the Rest of the Pipeline Flavio Vincenti, MD, San Francisco, United States
15:15 – 15:30	Break
15:30 – 17:00	<b>B-Cells and Antibody-Mediated Rejection</b> Chairs: Christophe Legendre, MD, <i>Paris, France</i> and Stefan Schneeberger, MD, <i>Innsbruck, Austria</i>
15:30	B-Cell Regulation Menna Clatworthy, MD, PhD
16:00	Diagnosis of Antibody-Mediated Rejection Alexandre Loupy, MD, PhD, <i>Paris, France</i>
16:30	Management of Antibody-Mediated Rejection Christophe Legendre, MD, <i>Paris, France</i>
17:00 – 18:00	Individualized Immunosuppression Chairs: Teun van Gelder, MD, PhD, <i>Rotterdam, The Netherlands</i> and Mohamed Sayegh, MD, <i>Boston, United States and Beirut, Lebanon</i>
17:00	How to Achieve True Individualized Therapy: Gene Sequencing, Biomarkers Andrew Kasarskis, PhD, <i>New York, United Sates</i>
17:30	Clinical Relevance of Pharmacogenetics of Recipients and Donors Dirk Kuypers, MD, PhD, <i>Leuven, Belgium</i>
18:00 – 19:30	Welcome Reception with Posters and Exhibits

## Saturday, October 13, 2012

09:00 – 10:30	<b>Biomarkers</b> Chairs: Teun van Gelder, MD, PhD, <i>Rotterdam, The Netherlands</i> and Rutger Ploeg, MD, PhD, <i>Oxford, United Kingdom</i>	
09:00	Immune Surveillance in Clinical Trials: What Did We Learn from RISET? Birgit Sawitzki, PhD, <i>Berlin, Germany</i>	
09:30	Clinical Trials in Organ Transplantation (CTOT) Donald Hricik, MD, <i>Cleveland, United States</i>	
10:00 - 10:30	Break	
10:30 – 11:30	<b>Current Pipelines in Biotech and Pharma</b> Chairs: Klemens Budde, MD, <i>Berlin, Germany</i> and Flavio Vincenti, MD, <i>San Francisco, United States</i>	
	Presentations from Biotech Companies and Pharmaceutical Companies	
11:30 – 12:30	Small Molecules in the Pipeline Chairs: Carla Baan, PhD, <i>Rotterdam, The Netherlands</i> and Robert Gaston, MD, <i>Birmingham, United States</i>	
11:30	Sotrastaurin Klemens Budde, MD, <i>Berlin, Germany</i>	
12:00	Tofacitinib Flavio Vincenti, MD, <i>San Francisco, United States</i>	
12:30 – 14:30	Long-term Outcomes in Kidney Transplantation with T-cell Costimulation Blockade Bristol-Myers Squibb Luncheon Symposium	
14:30 – 14:45	Break	
14:45 – 16:15	<b>Unfulfilled Targets in Transplantation</b> Chairs: Thomas Wekerle, MD, <i>Vienna, Austria</i> and Donald Hricik, MD, <i>Cleveland, United States</i>	
14:45	II6 and II17: Should These Cytokines Be Targeted? Carla Baan, PhD, <i>Rotterdam, The Netherland</i> s	
15:15	Targeting Memory Cells: The Next Hurdle Allan Kirk, MD, PhD, <i>Atlanta, United States</i>	
15:45	The Case for Targeting Complement Peter Heeger, MD, <i>New York, United States</i>	
16:15 – 17:45	<b>Challenging Medical Decisions</b> Chair: Klemens Budde, MD, <i>Berlin, Germany</i>	
16:15	Desensitize or Donor Swap? Robert Gaston, MD, <i>Birmingham, United States</i>	
16:45	Unacceptable Mismatches Frans Claas, PhD, <i>Leiden, The Netherlands</i>	
17:15	The mTor-inhibitor Dilemma: Who Benefits and Who Does Not Josep Grinyó, MD, <i>Barcelona, Spain</i>	

## Sunday, October 14, 2012

9:00 – 10:15	Moderated Walk-Around Poster Session with Breakfast
10:15 – 11:15	The Unmet Needs
10:15	New Molecules for Delayed Graft Function Bernd Schröppel, MD, New York, United States
10:45	New Molecules for Fibrosis Roslyn Mannon, MD, <i>Birmingham, United States</i>
11:15 – 11:45	Break
11:45 – 12:45	Controversies in Transplantation
11:45	What Is Currently Considered Optimal Therapy and Why Is It Still Failing Us in the Long-term? Christophe Legendre, MD, <i>Paris, France</i>
12:15	Is Chronic Rejection Inevitable? Barbara Murphy, MD, New York, United States